Article

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer

2024-11-11

Abstract excerpt

Drug resistance is a major obstacle to the long-term effectiveness of cancer therapies. Approximately 70% of breast cancer patients relapse after 5 years of treatment, and the lack of biomarkers associated with drug resistance translates to poor prognosis in clinic. Previous research has utilised omics approaches to uncover biomarkers driving drug resistance, with a strong emphasis on genetic mutations. Here, we i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e94f5264-4080-5b99-8f53-9444f6f1be7d
DOI: 10.1101/2024.11.08.621581

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancerDOI 10.1101/2024.11.08.621581Read

Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancerSemantic proximity Read

Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancerSemantic proximity Read

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic CancerSemantic proximity Read

Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesSemantic proximity Read

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectivesSemantic proximity Read

Discovery of Proteins Responsible for Resistance to Three Chemotherapy Drugs in Breast Cancer Cells Using Proteomics and Bioinformatics AnalysisSemantic proximity Read

Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance BiomarkersSemantic proximity Read

Biomarkers and Multiple Drug Resistance in Breast CancerSemantic proximity Read

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity Read

The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast CancerSemantic proximity Read

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerSemantic proximity Read

Molecular basis for therapy resistanceSemantic proximity Read